Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33743408/

Non─small cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, which share relevant clinical features and therapeutic strategies. The homology between the tyrosine kinase domains of ROS1 and ALK defines unique subsets of patients highly ...